- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
OASIS, AJL Ophthalmic to distribute corneal implants
OASIS Medical Inc. and Spain-based AJL Ophthalmic SA have announced an exclusive relationship for the sales and distribution of corneal implants (Intacs) for the treatment of keratoconus and the FDA-approved treatment of myopia.
Glendora, CA-OASIS Medical Inc. and Spain-based AJL Ophthalmic SA have announced an exclusive relationship for the sales and distribution of corneal implants (Intacs) for the treatment of keratoconus and the FDA-approved treatment of myopia.
Addition Technologies, acquired by AJL Ophthalmic in January 2013, will continue the manufacturing and remain the FDA-approved Humanitarian Device Exemption holder of the device.
“OASIS is honored to work with AJL Ophthalmic and the (device),” said Craig Delgado, president of OASIS. “(This corneal implant) serves keratoconus patients, giving them a truly extraordinary option to retain their visual acuity once contacts or glasses are no longer a viable option.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
